Skip Navigation


JAC Advance Access originally published online on November 1, 2002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
50/6/933    most recent
dkf241v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by John, M. A.
Right arrow Articles by Hussain, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by John, M. A.
Right arrow Articles by Hussain, Z.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 933-938
© 2002 The British Society for Antimicrobial Chemotherapy

In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci

M. A. John1,2, C. Pletch1 and Z. Hussain1,2,*

1 Department of Microbiology & Infection Control, London Health Sciences Centre; 2 University of Western Ontario, London, Ontario, Canada

Received 18 January 2002; returned 17 July 2002; revised 28 August 2002; accepted 10 September 2002

Objectives: To determine in vitro susceptibilities of a large series of speciated coagulase-negative staphylococci (CNS) against three new antibiotics, linezolid, quinupristin/dalfopristin and telithromycin.

Methods: Susceptibilities to three new antibiotics and oxacillin, vancomycin, clindamycin and erythromycin were determined by the agar dilution method, as described by the NCCLS.

Results: Resistance to linezolid was not observed in any isolates, although MIC90 values varied between species. Fifteen of 658 (2.3%) isolates were resistant to quinupristin/dalfopristin, but <1% of the clinically most important isolates of Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus hominis demonstrated resistance to this agent. Susceptibility to clindamycin correlated with susceptibility to quinupristin/dalfopristin; however, resistance to clindamycin did not predict quinupristin/dalfopristin resistance. Telithromycin was the least active of the new agents tested, showing activity similar to that of clindamycin. Susceptibility and resistance to clindamycin were predictive of susceptibility and resistance to telithromycin.

Conclusion: Clindamycin susceptibility can be used as a surrogate marker for susceptibility to quinupristin/dalfopristin and telithromycin. Quinupristin/dalfopristin and linezolid show good activity against both mecA-positive and -negative CNS.

* Corresponding author. Tel: +1-519-685-8149; Fax: +1-519-685-8203; E-mail: Zafar.hussain{at}lhsc.on.ca


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
M. Miragaia, J. A. Carrico, J. C. Thomas, I. Couto, M. C. Enright, and H. de Lencastre
Comparison of Molecular Typing Methods for Characterization of Staphylococcus epidermidis: Proposal for Clone Definition
J. Clin. Microbiol., January 1, 2008; 46(1): 118 - 129.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
F. Trueba, E. Garrabe, R. Hadef, R. Fabre, J.-D. Cavallo, K. Tsvetkova, and O. Chesneau
High Prevalence of Teicoplanin Resistance among Staphylococcus epidermidis Strains in a 5-Year Retrospective Study.
J. Clin. Microbiol., May 1, 2006; 44(5): 1922 - 1923.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.